Prostamax is the prostate peptide of the Khavinson bioregulator family: a synthetic tetrapeptide, Lys-Glu-Asp-Pro (KEDP). Men buy it for benign prostatic hyperplasia (BPH), chronic prostatitis or general “prostate longevity”, often alongside Testagen.
The verdict: the published work on Prostamax is about chromatin in blood cells and prostate tissue in a dish. There is no study of urinary symptoms, prostate volume or PSA in men. Community experience is genuinely mixed.
For the whole class, see the peptide bioregulators overview.
At a Glance
| Property | Detail |
|---|---|
| Sequence | Lys-Glu-Asp-Pro (KEDP), synthetic tetrapeptide |
| Origin | Khavinson group, St. Petersburg |
| Proposed mechanism | Chromatin decondensation and gene reactivation (lymphocyte studies); stimulation of prostate tissue growth in culture |
| Marketed for | BPH, chronic prostatitis, prostate aging |
| Route | SC injection (research vials); oral prostate product in the family is the extract Libidon (Cytomax) |
| Typical dose range | 250 µg–2 mg SC daily for 10–40 days (practice); up to 5 mg reported |
| Evidence level | Limited: in-vitro and rat tissue studies only |
| Regulatory status | Not FDA- or EMA-approved; research chemical; not named by WADA, falls under S0 |
How it works
In lymphocytes taken from people aged 75–88, Prostamax was one of five peptides that reactivated ribosomal genes and loosened age-condensed chromatin, including the pericentromeric region of chromosome 1 [1]. Calorimetry showed a partial relaxation of chromatin fibres in human lymphocytes [2]. A Georgian study in lymphocytes from people aged 75–86 found that Prostamax roughly doubled the frequency of sister-chromatid exchanges (12.0 versus 5.9 per cell) and increased active nucleolar organiser regions [3]. In rat prostate explants, Prostamax at 0.05 ng/ml stimulated tissue growth [4].
Two observations deserve more attention than they get. More sister-chromatid exchanges is usually read as a sign of DNA stress, although the authors interpret it as chromatin “opening”. And a peptide that stimulates prostate tissue growth is an odd choice for an enlarged prostate.
What the evidence shows
Human studies
None. No trial of Prostamax in BPH, prostatitis or any other condition is indexed on PubMed.
Cell and animal studies
| Study | Model | Finding |
|---|---|---|
| Khavinson et al. 2004 [1] | Lymphocytes, people aged 75–88 | Ribosomal-gene activation, chromatin decondensation |
| Meskhi et al. 2004 [2] | Human lymphocytes, calorimetry | Partial relaxation of chromatin fibres |
| Dzhokhadze et al. 2012 [3] | Lymphocytes, people aged 75–86 | Sister-chromatid exchanges doubled; more active NORs |
| Zakutskii et al. 2006 [4] | Rat prostate explants | Stimulated tissue growth |
Dosing
For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.
| Goal | Dose | Route | Frequency / timing | Cycle length | Basis |
|---|---|---|---|---|---|
| Standard prostate course | 1–2 mg | SC injection | Once daily | 10–20 days (one 20 mg vial), 1–3 courses a year | Practice protocol (ZyraTrack forum, r/peptidebioregulators) |
| Long low-dose course | 500 µg | SC injection | Once daily | 40 days, with baseline PSA and testosterone | Practice protocol (vendor-founder protocol cited on PeptideCritic); 200 µg starting dose suggested in the same thread |
| Titrated start | 250 µg, rising to 500 µg | SC injection | Once daily | Not stated; PSA checked before and after | Anecdotal (eRoids forum) |
| Higher-dose BPH course | 5 mg | SC injection | Once daily | About 1 month | Anecdotal (r/Prostatitis) |
| Men’s stack | Prostamax 500 µg + Testagen 2 mg + Vesugen 1 mg | SC injection | Daily | 10–40 days depending on compound | Anecdotal (PeptideCritic) |
| Oral alternative (Libidon, Cytomax) | 1–2 capsules | Oral | 1–2 times daily | 30 days, 1–2 times a year | Label (supplement directions; PeptideDeck summary) |
The developer’s patent describes 0.01–100 µg per kg (PeptideDeck summary), which for a 70 kg man spans 0.7 µg to 7 mg. That range covers every protocol above and tells you nothing about which is right. Injection technique: peptide injection guide.
What people report: what works and what doesn’t
Reported to work
- Some men with BPH describe a stronger urinary stream and less discomfort within about five days at 5 mg a day (r/Prostatitis).
- Users who ran three rounds of Prostamax with Cartalax describe it as worth repeating (ZyraTrack forum).
Mixed or unclear
- Men starting Prostamax often plan before-and-after PSA and testosterone tests, but results are rarely posted (PeptideCritic, eRoids forum).
Reported not to work / disappointing
- In the same BPH thread, another user found a 1 mg daily course did nothing, and one reported marked prostate pain (r/Prostatitis).
BPH symptoms fluctuate and respond strongly to placebo, so a real trial would need IPSS symptom scores, flow rate and prostate volume against placebo over at least three months.
Safety and side effects
- No human safety data. Prostate pain has been reported by a user.
- Rule out prostate cancer first. Urinary symptoms in older men need a PSA and examination; a peptide must not delay diagnosis.
- Chromatin and SCE signal in vitro [3]: of unclear meaning; another reason for caution in anyone with a cancer history.
- Tissue-growth stimulation in rat prostate explants [4] sits uneasily with use for an enlarged prostate.
- Product quality: unregulated vials vary in content and sterility.
Legal and regulatory status
- US: not FDA-approved; “research use only” products are not approved for human use.
- EU / Germany: not authorised as a medicine by the EMA or BfArM.
- Sport: not named on the WADA 2026 list; falls under S0.
How it fits
For BPH, alpha-blockers, 5-alpha-reductase inhibitors, tadalafil and several procedures have randomised evidence. Prostamax has none. It is usually combined with Testagen and Vesugen in men’s protocols.
Related Articles
- Peptide Bioregulators: The Khavinson Protocol and What the Evidence Shows
- Kisspeptin: The Master Hormone Peptide for LH, Testosterone, and Fertility
- How to Inject Peptides: A Step-by-Step Guide
- Peptide Safety: What You Need to Know
Frequently asked questions
What is Prostamax?
Prostamax is the synthetic tetrapeptide Lys-Glu-Asp-Pro (KEDP) from the Khavinson bioregulator programme, marketed for the prostate gland.
Does Prostamax help BPH?
There is no human trial. Community reports are split between improvement, no effect and, occasionally, prostate pain. Proven BPH treatments exist and should not be replaced.
What dose of Prostamax do people use?
Reported injectable protocols range from 250–500 µg daily for up to 40 days, to 1–2 mg daily for 10–20 days, to 5 mg daily. The developer's patent describes 0.01–100 µg per kg. No human dose has been tested.
Can Prostamax affect PSA?
Unknown. No study has measured PSA in people taking Prostamax. Anyone using it should have a baseline PSA, because a peptide must never mask or delay a prostate cancer diagnosis.
Is Prostamax the same as Prostatilen or Libidon?
No. Prostatilen is a natural prostate extract used as a drug in Russia, and Libidon is a prostate extract in capsules (Cytomax). Prostamax is a single synthetic tetrapeptide.
References
- Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004. https://pubmed.ncbi.nlm.nih.gov/15085253/
- Meskhi T, Khachidze D, Barbakadze Sh, et al. The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ (in Russian). Biofizika. 2004. https://pubmed.ncbi.nlm.nih.gov/15612551/
- Dzhokhadze TA, Buadze TZh, Gaiozishvili MN, et al. Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro) (in Russian). Georgian Med News. 2012. https://pubmed.ncbi.nlm.nih.gov/23221144/
- Zakutskii AN, Chalisova NI, Ryzhak GA, et al. The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats (in Russian). Adv Gerontol. 2006. https://pubmed.ncbi.nlm.nih.gov/17152728/
Disclaimer: This article is for informational and educational purposes only and is not a prescription or individual medical advice. Prostamax is not approved by the FDA or the EMA.
